UCB Predicts Briviact Sales Of €450m by 2026; Plans New Partnerships
Executive Summary
UCB says its early to mid-stage pipeline contains 10 promising breakthrough molecules, some of which it aims to partner with other pharma players as part of its open innovation strategy.